DOAC Reversal: How We Reverse Eliquis, Xarelto, and Pradaxa When Bleeding Happens

A 72-year-old woman sits across from me in clinic with a new diagnosis of atrial fibrillation. Her CHA2DS2-VASc score is 4. She needs anticoagulation to prevent a stroke, and the data on apixaban for someone like her is excellent. She listens, nods, and then says what so many patients say in this exact moment: "But doctor, I heard you can't reverse those new blood thinners. If I fall and hit my head, that's it." She has talked to her sister. Her sister talked to a friend. The friend's husband had a bad outcome on warfarin years ago and somebody at some point told somebody else that the new agents have no antidote. By the time the rumor reached my exam room, it had hardened into fact. It isn't fact, and the gap between what patients have heard and what's actually true at the bedside in 2026 is one of the most consequential misunderstandings in cardiology right now.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. The fear that direct oral anticoagulants (DOACs) cannot be reversed has held a lot of patients back from a treatment that would lower their stroke risk by 60 to 70 percent. The fear made sense in 2010 when DOACs first hit the market without specific antidotes. It doesn't make sense in 2026. We have idarucizumab (Praxbind) for dabigatran. We have andexanet alfa (Andexxa) for apixaban and rivaroxaban. We have prothrombin complex concentrate (PCC) as an off-label option when the specific agents aren't available. We have short DOAC half-lives that make elective surgery straightforward. And we have years of real-world data showing that bleeding on a DOAC is generally less common and less severe than bleeding on warfarin. This article walks through how reversal actually works, what's available where, and why the fear that "you can't reverse a DOAC" is mostly a leftover from a problem we've already solved.

Why This Question Matters So Much

Atrial fibrillation roughly quintuples the risk of stroke, and the strokes caused by AFib tend to be larger and more disabling than other stroke types. The clot forms in the left atrial appendage, gets ejected when the rhythm changes or when the appendage finally squeezes out a piece of stagnant blood, and travels straight to the brain. Anticoagulation prevents that. The data on this is as solid as cardiology data gets: large randomized trials over decades have shown that anticoagulation in AFib patients with meaningful stroke risk reduces stroke by about two-thirds. The number needed to treat is small, the benefit is durable, and the risk of bleeding, while real, is generally outweighed by the stroke prevention in patients with elevated CHA2DS2-VASc scores.

The catch is that anticoagulation works by interfering with clotting, which means bleeding is the price you pay. Most bleeds on anticoagulants are minor: a nosebleed, a bruise, a small cut that takes longer to stop. Some bleeds are major: a gastrointestinal bleed requiring transfusion, a urinary tract bleed, or, in the worst case, an intracranial hemorrhage. The fear that drives so many patients to refuse anticoagulation isn't really fear of nuisance bleeding. It's fear of the catastrophic intracranial bleed, the head injury after a fall, the operation where the surgeon needs to stop the blood thinning fast and can't.

When that fear was a fair description of reality, it kept some patients alive who would have bled on warfarin without a way to stop it. The data tells us, though, that more patients died of strokes they would have prevented by taking anticoagulation than ever bled fatally because reversal failed. And the fear has become detached from current practice. We can reverse DOACs now. We do it routinely in emergency departments and operating rooms. The mechanics of reversal are different from warfarin, sometimes faster, sometimes more expensive, but the outcomes are good when the right agent is given at the right time.

The DOACs in Use

Four DOACs are commonly prescribed in the United States, and understanding their mechanisms helps make sense of how reversal works. They split into two categories based on what they inhibit in the clotting cascade.

Dabigatran (Pradaxa) is a direct thrombin inhibitor. Thrombin, also known as factor IIa, is the enzyme that converts fibrinogen to fibrin in the final step of clot formation. Dabigatran binds thrombin directly and prevents it from doing its job. The drug is a prodrug, meaning it's absorbed as dabigatran etexilate and converted to active dabigatran in the body. Its half-life is around 12 to 17 hours and depends heavily on kidney function, since the drug is largely cleared by the kidneys.

Apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa) are factor Xa inhibitors. Factor Xa sits one step earlier in the clotting cascade than thrombin and is what activates thrombin. By inhibiting factor Xa, these drugs reduce thrombin generation and slow the formation of fibrin. Apixaban has a half-life around 12 hours and is dosed twice daily. Rivaroxaban has a half-life around 5 to 13 hours and is usually dosed once daily. Edoxaban has a half-life around 10 to 14 hours and is dosed once daily. Apixaban is the most commonly prescribed DOAC in the US, partly because of its favorable bleeding profile in the ARISTOTLE trial.

The mechanistic split matters because reversal agents are mechanism-specific. Idarucizumab works only on dabigatran because it's a monoclonal antibody fragment designed to bind dabigatran. Andexanet alfa works on factor Xa inhibitors because it's a modified factor Xa molecule that acts as a decoy. Each agent solves a different problem.

DOAC Pharmacokinetics Matter More Than People Realize

Before we get to specific antidotes, there's a simpler point that often gets lost. DOACs have short half-lives. Warfarin has a half-life around 36 to 42 hours, which means after you stop the drug, it sticks around for days. The INR takes time to drop. DOACs clear from the body in hours, not days. For someone with normal kidney function on apixaban, the drug is mostly gone within 24 to 36 hours of the last dose. Rivaroxaban clears similarly. Dabigatran depends more heavily on kidney function but follows the same general pattern.

For elective surgery, this changes everything. A patient on warfarin who needs a hip replacement traditionally had to stop the drug 5 days before surgery, sometimes with bridging heparin in between, with INR checks throughout. A patient on apixaban can stop the drug 48 hours before most procedures and walk into surgery with no anticoagulant effect on board. For low-bleeding-risk procedures, sometimes 24 hours is enough. For high-bleeding-risk procedures or patients with reduced kidney function, we extend the window to 72 hours or longer. The point is that for elective situations, simply stopping the drug works. We don't need a specific antidote. We need a calendar.

For emergency situations, the same principle applies on a compressed timeline. A patient who took apixaban this morning and shows up with a bleeding ulcer this evening will have less drug on board in 12 hours than they have right now. If the bleeding can be controlled with endoscopic intervention and supportive care during that window, no specific reversal agent is required. The body clears the drug, the kidneys do their work, and the anticoagulant effect fades. Reversal agents are reserved for situations where the bleeding is severe enough or surgery is urgent enough that we can't wait for natural clearance.

Idarucizumab (Praxbind) for Dabigatran

Idarucizumab is the cleanest reversal story in the DOAC space. It's a humanized monoclonal antibody fragment that binds dabigatran with an affinity about 350 times higher than dabigatran's affinity for thrombin. When you give idarucizumab, it scavenges dabigatran out of circulation almost instantly. The anticoagulant effect of dabigatran disappears within minutes.

The drug was approved by the FDA in 2015 based on the RE-VERSE AD trial, a study of 503 patients who had either life-threatening bleeding or needed urgent surgery while on dabigatran. Patients received 5 grams of intravenous idarucizumab in two 2.5-gram doses. Anticoagulant effect, measured by dilute thrombin time and ecarin clotting time, normalized within minutes in nearly every patient. The drug was well-tolerated. There were no signals of pro-thrombotic effects from the antibody itself, which makes sense since the antibody binds dabigatran without affecting any other component of clotting.

In practice, when a patient on dabigatran shows up with intracranial hemorrhage or needs an emergency operation, idarucizumab is the first-line agent. It's stocked at most major hospitals. It works fast. It doesn't carry the thrombotic concerns that other reversal agents carry. After the bleeding is controlled or the surgery is done, dabigatran can usually be restarted within a day or two depending on the clinical picture.

Andexanet Alfa (Andexxa) for Apixaban and Rivaroxaban

Andexanet alfa is the reversal agent for factor Xa inhibitors. It's a recombinant modified factor Xa molecule that's been engineered to bind factor Xa inhibitors without itself participating in the clotting cascade. When you infuse it, the drug acts as a decoy: apixaban or rivaroxaban molecules in circulation bind to the modified Xa instead of binding to native factor Xa, freeing up endogenous factor Xa to do its job in the clotting cascade.

Approval came in 2018 based on the ANNEXA-4 trial, a study of patients with major bleeding while taking a factor Xa inhibitor. Anti-factor Xa activity dropped by about 90 percent during the bolus infusion, with hemostatic efficacy rated as excellent or good in about 80 percent of patients at 12 hours. The drug clearly works at neutralizing the anticoagulant effect.

Two practical issues complicate andexanet's use. The first is cost. The drug is expensive, with a single dose running into the tens of thousands of dollars. The second is access. Not every hospital stocks it, and even those that do may have stocking and protocol restrictions. Smaller community hospitals are more likely to use PCC instead, which is cheaper and more widely available. The third issue, which I include because it's part of the honest conversation: ANNEXA-4 and subsequent data have raised questions about thrombotic events after andexanet use. The drug neutralizes the anticoagulant, which is the goal, but in doing so it also removes the protection against the underlying thrombotic state. Roughly 10 percent of patients in ANNEXA-4 had a thrombotic event in the 30 days after andexanet, including stroke, MI, and DVT or PE. Some of these likely reflect the underlying disease (the patient had AFib, lost their anticoagulation, and had a stroke), but some may reflect a pro-thrombotic effect of andexanet itself, possibly through inhibition of tissue factor pathway inhibitor. The clinical implication is that anticoagulation should be restarted as soon as the bleeding is controlled, often within 1 to 2 days.

For a patient with a life-threatening intracranial hemorrhage on apixaban or rivaroxaban at a hospital that stocks andexanet, the agent is given. For a patient with the same bleed at a hospital that doesn't stock it, PCC is given off-label. The clinical outcomes between these two approaches are still being studied, with no clear winner in head-to-head comparisons.

PCC (4-Factor Prothrombin Complex Concentrate)

Four-factor prothrombin complex concentrate, sold as Kcentra in the US, contains factors II, VII, IX, and X along with proteins C and S. It was originally approved for warfarin reversal, where it works beautifully because warfarin depletes those exact factors. For DOACs, PCC is used off-label. The mechanism is different: PCC doesn't bind or remove the DOAC the way idarucizumab or andexanet does. It overwhelms the system with extra clotting factors, pushing the cascade forward despite the DOAC's inhibitory effect.

The data on PCC for DOAC reversal is observational rather than randomized. Several studies have shown reasonable hemostatic outcomes when PCC is given for DOAC-associated major bleeding, with response rates in the 65 to 80 percent range depending on the study and the bleeding type. The dose is typically 25 to 50 units per kilogram of body weight. PCC works for both factor Xa inhibitors and dabigatran, though for dabigatran the activated PCC formulations (FEIBA, which contains activated factor VII) sometimes have an edge.

PCC has practical advantages over the specific antidotes. It's cheaper. It's stocked at virtually every hospital. It can be given quickly. The disadvantages are that it's less specific, doesn't actually remove the DOAC from circulation, and carries some risk of thrombotic events because you're giving extra clotting factors to a patient who's at baseline pro-thrombotic. In emergency department practice, PCC is often the first agent given for DOAC-associated bleeding when andexanet isn't available or when waiting for it would delay treatment.

Edoxaban Reversal

Edoxaban is the least commonly prescribed of the four DOACs in the US, but it does have its niche. Andexanet isn't approved for edoxaban reversal, but it's been used off-label with reasonable results. PCC is also used. The pharmacokinetics of edoxaban are similar to the other Xa inhibitors, so the same general principles apply: short half-life, clearance over 24 to 36 hours, andexanet or PCC for emergency reversal.

Major Bleeding Management Goes Beyond Reversal Agents

Reversing the anticoagulant is one piece of bleeding management, not the whole picture. A patient with major bleeding on a DOAC needs the same comprehensive resuscitation any bleeding patient needs. Airway, breathing, circulation. IV access, type and crossmatch, hemoglobin checks, lactate, coagulation studies. Transfusion of packed red cells if hemoglobin drops below threshold. Source control, whether that's endoscopy for a GI bleed, interventional radiology for a vascular bleed, or neurosurgery for a hematoma needing evacuation. Vasopressor support if blood pressure can't be maintained with volume alone.

The reversal agent stops the anticoagulant effect. It doesn't stop the bleeding. If a patient has a perforated peptic ulcer, no amount of idarucizumab or andexanet will fix that without endoscopic clipping or surgical repair. If a patient has a subdural hematoma that's expanding, neurosurgery is the definitive treatment, with reversal as a supporting intervention to make surgery safer. The job of the reversal agent is to take the DOAC out of the picture so that the body's natural clotting mechanisms and the surgeon's interventions can work. The bleeding stops because of the underlying repair, not because of the antidote alone.

Emergency Surgery on a DOAC

Emergency surgery presents a different scenario than active bleeding. The patient isn't bleeding right now, but they need an operation in the next few hours, and the surgeon doesn't want to operate on someone with active anticoagulation. The decision tree depends on three things: when was the last DOAC dose, what's the kidney function, and how urgent is the surgery.

If the last dose was more than 24 hours ago and kidney function is normal, the drug is mostly cleared and surgery can usually proceed without specific reversal. We sometimes check a DOAC level if it's available and the situation is borderline. If the last dose was within 12 hours and the surgery cannot wait, reversal is given: idarucizumab for dabigatran, andexanet or PCC for the Xa inhibitors. If the surgery is moderately urgent (within the next 12 to 24 hours), we sometimes wait for natural clearance and proceed with normal coagulation, depending on the bleeding risk of the procedure.

Reduced kidney function changes the calculation, especially for dabigatran. A patient with creatinine clearance below 30 mL/min may have dabigatran on board for days after the last dose. Andexanet and PCC don't depend on kidney function for their effect, so they work regardless. Idarucizumab also works regardless. The question is whether reversal is needed, and the answer depends on how much drug is still active and how urgent the surgery is.

Bridging therapy with heparin used to be a routine consideration for warfarin patients having surgery. For DOAC patients, bridging is rarely needed because the drug clears so fast. The patient stops the DOAC, has the surgery, and restarts the DOAC once hemostasis is secure, often within 24 to 48 hours postoperatively. The convenience of this approach is one of the underrated benefits of DOACs over warfarin.

Comparison to Warfarin Reversal

Warfarin has been around since the 1950s and we know how to reverse it. The mechanisms are well-established. Vitamin K replenishes the depleted clotting factors, but it takes 12 to 24 hours to work because the liver has to synthesize new factors. Fresh frozen plasma provides the missing factors directly but requires large volumes to achieve full reversal, sometimes liters, and carries risks of fluid overload, transfusion-related acute lung injury, and ABO incompatibility. Four-factor PCC (Kcentra) reverses warfarin within minutes by providing concentrated factors II, VII, IX, and X without the volume burden of FFP.

In contemporary practice, warfarin reversal for major bleeding usually means PCC plus vitamin K, with FFP reserved for situations where PCC isn't available. Vitamin K alone is reserved for non-emergent reversal where you have time to wait. The reversal of warfarin is straightforward, well-studied, and effective.

DOAC reversal is similarly effective when the right agent is used. The differences are mechanistic and logistical. Idarucizumab and andexanet are specific antidotes that work fast and cleanly, but they're newer and more expensive and not stocked everywhere. PCC bridges the gap. Warfarin's edge for decades was that we had a clear reversal protocol; DOACs were perceived as having no antidote. That perception is now out of date.

Real-World Bleeding Rates

A point that often gets buried in the reversal conversation: DOACs bleed less than warfarin in most populations. The large trials (ARISTOTLE for apixaban, RE-LY for dabigatran, ROCKET AF for rivaroxaban, ENGAGE AF-TIMI 48 for edoxaban) all compared each DOAC to dose-adjusted warfarin and showed lower rates of intracranial hemorrhage with the DOACs. Apixaban in ARISTOTLE had about 50 percent less intracranial bleeding than warfarin and lower major bleeding overall. The other DOACs showed similar or slightly less favorable patterns, but all came out at least as safe as warfarin and meaningfully safer for the brain.

Real-world data has confirmed these findings, though with the variation you'd expect from observational studies. Patients on DOACs in clinical practice have lower rates of intracranial hemorrhage than patients on warfarin. They have similar or lower rates of major bleeding overall. They have somewhat higher rates of GI bleeding, mostly with rivaroxaban and dabigatran rather than apixaban. The net safety profile favors DOACs.

When you combine the lower bleeding rates with the availability of reversal agents, the case for choosing a DOAC over warfarin in most AFib patients is strong. The exceptions are mechanical heart valves (where warfarin is still required) and severe kidney disease (where dose adjustment or alternative anticoagulation is needed), but for the typical AFib patient with normal-to-moderate kidney function, a DOAC is usually the right answer.

Why Patients Should Not Delay Anticoagulation Out of Reversal Fear

Coming back to the patient I described at the start. Her stroke risk on no anticoagulation is somewhere around 4 to 5 percent per year. Over 10 years, that's a meaningful chance of a stroke that could leave her unable to walk or speak. With apixaban, her stroke risk drops to about 1.5 percent per year. Her risk of major bleeding goes up modestly, with intracranial hemorrhage staying very low. If she does bleed, we have tools to reverse the drug and stop the bleeding. The math, for someone in her risk profile, is heavily in favor of taking the medication.

The fear of being unable to reverse a DOAC was a reasonable concern in 2010. It isn't anymore. Patients who refuse anticoagulation today because of that fear are accepting a much larger stroke risk to avoid a smaller and now manageable bleeding risk. The conversation I have with patients in this situation is direct: the risk you're afraid of is no longer the biggest risk in the room. The biggest risk is the stroke we could have prevented.

Common Patient Questions

If I have a fall and hit my head while on a DOAC, what happens?

You go to the emergency department. They get a CT scan of your head. If there's a bleed, they administer a reversal agent: idarucizumab if you're on dabigatran, andexanet or PCC if you're on apixaban or rivaroxaban. The drug stops working within minutes for idarucizumab, and within tens of minutes for andexanet. Neurosurgery evaluates whether intervention is needed. Most patients with small bleeds are managed with reversal and observation; larger bleeds may need surgical evacuation. The outcomes are often good, especially when reversal is given quickly.

Do all hospitals have these reversal agents?

Most major hospitals stock idarucizumab and PCC. Andexanet stocking varies more, with academic centers and large community hospitals more likely to carry it than smaller facilities. If your hospital doesn't have andexanet, they'll use PCC for factor Xa inhibitor reversal. Both approaches work, even if andexanet has the more specific mechanism.

How fast do the reversal agents work?

Idarucizumab works within minutes of infusion. Andexanet works within minutes of the bolus, with continued effect during the maintenance infusion that follows. PCC takes 10 to 30 minutes to start showing effect. All three are fast enough to be clinically useful in emergency situations.

Is the reversal complete or partial?

Idarucizumab provides nearly complete reversal of dabigatran's anticoagulant effect for several hours, after which residual dabigatran from tissues can re-emerge if a second dose isn't given. Andexanet provides about 90 percent reduction in anti-factor Xa activity during infusion, with rebound after the infusion ends. PCC doesn't actually remove the DOAC; it pushes clotting forward despite the drug's continued presence. In all three cases, the reversal is sufficient to allow hemostasis and surgical intervention when needed.

After reversal, when can I restart my anticoagulant?

As soon as the bleeding is controlled and your team determines the risk of restarting is lower than the risk of going without anticoagulation. For a small intracranial hemorrhage, this might be 1 to 2 weeks. For a GI bleed that's been treated endoscopically, often within a few days. For a planned surgery, often within 24 to 48 hours postoperatively. The longer you go without anticoagulation, the higher your risk of a stroke from the underlying AFib, so we don't want to wait longer than necessary.

What if I need urgent surgery while taking a DOAC?

The team checks when your last dose was. If it was more than 24 hours ago and your kidneys work normally, the drug has mostly cleared and surgery can usually go ahead. If the last dose was recent and the surgery can't wait, a reversal agent is given before the operation. The decision is made jointly by the surgeon, the anesthesiologist, and your cardiologist or hospitalist.

Are DOACs riskier than warfarin?

For most patients, DOACs are safer than warfarin. The large trials and real-world data both show lower rates of intracranial hemorrhage with DOACs and similar or lower rates of major bleeding overall. There are exceptions, including mechanical heart valves and severe kidney disease, where warfarin or dose-adjusted DOACs are appropriate. For the typical AFib patient, a DOAC is usually the better choice.

What's the cost difference between andexanet and PCC?

Andexanet costs roughly $25,000 to $50,000 per dose depending on the dosing tier, which is selected based on the DOAC level and time since last dose. PCC runs around $3,000 to $6,000 per dose. The cost difference is one of the reasons PCC remains widely used, especially at hospitals where andexanet isn't routinely stocked.

When to Escalate Care

Call 911 immediately for any signs of major bleeding while on a DOAC: vomiting blood, passing large amounts of blood in the stool or urine, sudden severe headache, weakness or numbness suggestive of stroke, severe unexplained back or abdominal pain, or fall with head injury. Time to reversal matters, and the sooner you get to the emergency department, the sooner reversal can start if it's needed.

Contact your cardiologist or primary care doctor the same day for new-onset bruising that seems excessive, prolonged minor bleeding (a cut that won't stop, a nosebleed lasting more than 20 minutes), blood in the urine or stool that isn't large in volume but is new, or any other concerning bleeding symptom. Same-day evaluation lets us check labs, assess whether the dose needs adjustment, and rule out other contributing conditions.

Schedule a clinic visit within one to two weeks for routine questions about your anticoagulation, dose timing around procedures, dental work or minor surgery planning, or any general concerns. Most DOAC questions don't need an emergency visit; they need a thoughtful conversation with your team.

A Final Note From Me

The story of DOAC reversal is one of the most rapidly evolving areas in cardiology over the past decade. When I was in training, the line was that DOACs had no antidote and patients should know that going in. That was true at the time, and we made decisions accordingly. Today, that line is wrong. Idarucizumab reverses dabigatran in minutes. Andexanet reverses apixaban and rivaroxaban. PCC fills in when the specific agents aren't available. The fear that drove patients away from these medications has become detached from current practice, and patients who carry that fear today are often making a decision based on outdated information.

If you're someone who has been hesitant to start a DOAC because of the reversal question, I'd encourage you to revisit the conversation with your cardiologist. Ask about the specific risks for your situation. Ask about the data on stroke prevention and bleeding rates for your specific scenario. Ask about reversal availability at the hospital you'd most likely go to in an emergency. The answers will probably surprise you in a reassuring direction.

If you're already on a DOAC and you're worried about what would happen if you bled, know that the systems for handling that scenario are well-developed. Emergency departments deal with DOAC-associated bleeding routinely. The protocols are established. The agents are stocked. The outcomes for patients who get prompt reversal are generally good. Your job is to recognize concerning bleeding and get to care quickly. Our job, on the receiving end, is to do what we've trained to do, with tools that didn't exist a decade ago and that work better than the alternatives we used to have.

References

1. Pollack, Charles V., Paul A. Reilly, Joanne van Ryn, et al. "Idarucizumab for Dabigatran Reversal: Full Cohort Analysis." New England Journal of Medicine 377, no. 5 (2017): 431-441.

2. Connolly, Stuart J., Truman J. Milling, John W. Eikelboom, et al. "Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors." New England Journal of Medicine 375, no. 12 (2016): 1131-1141.

3. Granger, Christopher B., John H. Alexander, John J. V. McMurray, et al. "Apixaban versus Warfarin in Patients with Atrial Fibrillation." New England Journal of Medicine 365, no. 11 (2011): 981-992.

4. Connolly, Stuart J., Michael D. Ezekowitz, Salim Yusuf, et al. "Dabigatran versus Warfarin in Patients with Atrial Fibrillation." New England Journal of Medicine 361, no. 12 (2009): 1139-1151.

5. Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al. "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation." New England Journal of Medicine 365, no. 10 (2011): 883-891.

6. Giugliano, Robert P., Christian T. Ruff, Eugene Braunwald, et al. "Edoxaban versus Warfarin in Patients with Atrial Fibrillation." New England Journal of Medicine 369, no. 22 (2013): 2093-2104.

7. Joglar, Jose A., Mina K. Chung, Anastasia L. Armbruster, et al. "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation." Journal of the American College of Cardiology 83, no. 1 (2024): 109-279.

8. Hindricks, Gerhard, Tatjana Potpara, Nikolaos Dagres, et al. "2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation." European Heart Journal 42, no. 5 (2021): 373-498.

9. Witt, Daniel M., Robby Nieuwlaat, Nathan P. Clark, et al. "American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Optimal Management of Anticoagulation Therapy." Blood Advances 2, no. 22 (2018): 3257-3291.

10. Tomaselli, Gordon F., Kim K. Mahaffey, Adam Cuker, et al. "2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants." Journal of the American College of Cardiology 76, no. 5 (2020): 594-622.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.